CocrystalPharmaInc.jpg
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
November 13, 2018 11:50 ET | Cocrystal Pharma, Inc.
- Company’s novel, broad spectrum influenza antivirals specifically designed to be effective against all significant A strains of the influenza virus -  - CC-43244, Company’s lead molecule has...
isco logo.jpg
International Stem Cell Corporation Doses Tenth Patient in Parkinson's Disease Clinical Trial
October 08, 2018 08:30 ET | International Stem Cell Corporation
CARLSBAD, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
isco logo.jpg
International Stem Cell Corporation Raised Funds Through a Private Placement at Premium to Market
October 02, 2018 08:00 ET | International Stem Cell Corporation
CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
CocrystalPharmaInc.jpg
Cocrystal Pharma Reports 2018 Second Quarter Financial Results and Provides Corporate Update
August 09, 2018 08:00 ET | Cocrystal Pharma, Inc.
– First half of 2018 marked by management’s successful execution of corporate, clinical and regulatory strategies – – Topline results from Phase 2a study evaluating CC-31244 for...
isco logo.jpg
International Stem Cell Corporation Expands Manufacturing Capabilities for Biomedical Products
July 10, 2018 07:00 ET | International Stem Cell Corporation
CARLSBAD, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing...
CocrystalPharmaInc.jpg
Cocrystal Pharma Commences Enrollment and Initiates Patient Dosing in Phase 2a Study Evaluating CC-31244 for the Treatment of HCV
June 28, 2018 07:35 ET | Cocrystal Pharma, Inc.
- Topline results from Phase 2a study expected to be announced before year end - ATLANTA, GA and BOTHELL, WA, June 28, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal”...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces Inclusion in Russell Microcap® Index
June 25, 2018 08:00 ET | Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, June 25, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...